drugset / Trial / NCT03452267

Insulin Signaling in Skeletal Muscle

NCT03452267

Phase 2/3 Withdrawn Wayne State University
RandomizedParallel-groupOpen-labelOther

Summary

The insulin sensitizing effects of metformin and pioglitazone in the skeletal muscle remain unknown. Our group aims to analyze molecular changes within the skeletal muscle of pre-diabetic patients through the use of a clinical trial in humans.

Timeline

Start
2019-09-01
Primary completion
2024-12
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 850 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral

Indications

No indication recorded.